Views of Wockhardt's Manufacturing Facilities As Indian Pharmaceuticals Breach Quality Control

Workers are reflected in a pool of water as they wait to enter the Wockhardt Ltd. manufacturing facility in the Chikalthana industrial area in Aurangabad, India, on Monday, Sept. 16, 2013. Wockhardt currently controls about 26 percent of the U.S. market for metoprolol, a generic version of the heart pill sold by London-based AstraZeneca Plc under the brand name Toprol-XL, according to Needham & Co. Metoprolol alone makes up about 14 percent of the company's 56 billion rupees in annual revenue. Photographer: Dhiraj Singh/Bloomberg via Getty Images
Workers are reflected in a pool of water as they wait to enter the Wockhardt Ltd. manufacturing facility in the Chikalthana industrial area in Aurangabad, India, on Monday, Sept. 16, 2013. Wockhardt currently controls about 26 percent of the U.S. market for metoprolol, a generic version of the heart pill sold by London-based AstraZeneca Plc under the brand name Toprol-XL, according to Needham & Co. Metoprolol alone makes up about 14 percent of the company's 56 billion rupees in annual revenue. Photographer: Dhiraj Singh/Bloomberg via Getty Images
Views of Wockhardt's Manufacturing Facilities As Indian Pharmaceuticals Breach Quality Control
LICENTIE KOPEN
Hoe mag ik dit beeld gebruiken?
€ 475,00
EUR

GEGEVENS

Beperkingen:
Neem voor gebruik voor alle commerciële of promotiedoeleinden contact op met uw lokale kantoor.For editorial use only. Additional clearance required for commercial or promotional use, contact your local office for assistance. Any commercial or promotional use of Bloomberg content requires Bloomberg's prior written consent.
Credits:
Bloomberg / Contributor
Redactioneel nr.:
181964987
Collectie:
Bloomberg
Gemaakt op:
16 september 2013
Datum van uploaden:
Soort licentie:
Release-informatie:
Geen release. Meer informatie
Bron:
Bloomberg
Naam materiaal:
INDIA WOCKHARDT